PT900380E - Metodos para seleccionar e produzir epitopos peptidicos de celulas t e vacinas que incorporam os referidos epitopos seleccionados - Google Patents

Metodos para seleccionar e produzir epitopos peptidicos de celulas t e vacinas que incorporam os referidos epitopos seleccionados

Info

Publication number
PT900380E
PT900380E PT97919749T PT97919749T PT900380E PT 900380 E PT900380 E PT 900380E PT 97919749 T PT97919749 T PT 97919749T PT 97919749 T PT97919749 T PT 97919749T PT 900380 E PT900380 E PT 900380E
Authority
PT
Portugal
Prior art keywords
epithopes
vaccines
methods
selecting
peptidic
Prior art date
Application number
PT97919749T
Other languages
English (en)
Inventor
Cornelis Joseph Maria Melief
Wybe Martin Kast
Sjoerd Henricus Van Der Burg
Reinaldus Everardus Maria Toes
Rienk Offringa
Original Assignee
Univ Leiden
Seed Capital Invest Sci B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Seed Capital Invest Sci B V filed Critical Univ Leiden
Publication of PT900380E publication Critical patent/PT900380E/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT97919749T 1996-04-26 1997-04-28 Metodos para seleccionar e produzir epitopos peptidicos de celulas t e vacinas que incorporam os referidos epitopos seleccionados PT900380E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201145 1996-04-26
EP96203670 1996-12-23

Publications (1)

Publication Number Publication Date
PT900380E true PT900380E (pt) 2003-12-31

Family

ID=26142751

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97919749T PT900380E (pt) 1996-04-26 1997-04-28 Metodos para seleccionar e produzir epitopos peptidicos de celulas t e vacinas que incorporam os referidos epitopos seleccionados

Country Status (11)

Country Link
US (1) US20070025968A1 (pt)
EP (1) EP0900380B1 (pt)
JP (1) JP4108126B2 (pt)
AT (1) ATE244891T1 (pt)
AU (1) AU738649B2 (pt)
CA (1) CA2252675A1 (pt)
DE (1) DE69723434T2 (pt)
DK (1) DK0900380T3 (pt)
ES (1) ES2205209T3 (pt)
PT (1) PT900380E (pt)
WO (1) WO1997041440A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
ATE377022T1 (de) * 1997-06-23 2007-11-15 Ludwig Inst Cancer Res Isolierte decapeptide, die an hla moleküle binden,sowie deren verwendung
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
GB9804121D0 (en) * 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
JP2002520000A (ja) * 1998-05-13 2002-07-09 エピミューン, インコーポレイテッド 免疫応答を刺激するための発現ベクターおよびそのベクターの使用方法
ES2249907T3 (es) * 1998-05-23 2006-04-01 Leiden University Medical Center Anticuerpos de union cd40 y peptidos ctl para el tratamiento de tumores.
DE69940774D1 (de) * 1998-06-17 2009-06-04 Idm Pharma Inc Hla-bindende peptide und ihre verwendungen
EP1105496B1 (en) * 1998-08-21 2007-03-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modified hcv peptide vaccines
US6962790B1 (en) 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
AU7917200A (en) * 1999-09-30 2001-04-30 Institut Pasteur Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
EP2177534A3 (en) 1999-11-18 2010-07-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
BR0017052B1 (pt) * 1999-12-28 2013-12-24 Epimmune Inc Método para a projeção de um constructo poliepitópico e constructo poliepitópico preparado pelo referido método
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
AU2001257410B8 (en) * 2000-04-28 2006-12-21 Mannkind Corporation Method of identifying and producing antigen peptides and use thereof as vaccines
DK1363938T3 (en) 2000-08-03 2014-03-24 Univ Johns Hopkins Molecular vaccine that connects an endoplasmic reticulum-chaperonepolypeptid with an antigen
US20030191063A1 (en) * 2000-08-21 2003-10-09 Wraith David Cameron Peptide selection method
EP1619207A3 (en) * 2000-09-01 2006-02-08 Epimmune Inc. HLA-A2.1 binding peptides derived from HCV and their uses
EP1425039A4 (en) * 2001-03-23 2005-02-02 Us Gov Health & Human Serv PEPTIDES THAT GIVE AN IMMUNE REACTION WITH THE HUMAN PAPILLOMA VIRUS
EP1752160A3 (en) * 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1392357A2 (en) * 2001-05-18 2004-03-03 Powderject Vaccines, Inc. Vaccine composition
CA2469738A1 (en) 2001-11-07 2003-08-07 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
JP2008044848A (ja) * 2004-11-30 2008-02-28 Univ Kurume Hla−a24拘束性腫瘍抗原ペプチド
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2023143A1 (en) 2007-08-06 2009-02-11 Boehringer Ingelheim Vetmedica Gmbh Immunogenic streptococcus proteins
EP2280731A1 (en) 2008-04-09 2011-02-09 Technion Research and Development Foundation, Ltd. Anti human immunodeficiency antibodies and uses thereof
CA2836494C (en) 2011-05-24 2023-01-03 Biontech Ag Individualized vaccines for cancer
WO2013019658A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP3417874B1 (en) 2012-11-28 2024-09-11 BioNTech SE Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种宫颈癌相关的热休克蛋白复合物及其应用
JPWO2019054409A1 (ja) * 2017-09-12 2020-11-12 国立大学法人北海道大学 Hlaタンパク質に相互作用する物質のスクリーニング方法及びスクリーニング用キット
AU2018437560A1 (en) * 2018-08-23 2021-02-18 Grid Powr (Australia) Pty Ltd Process and device for improving of synthesis and/or flue gas velocity field for refuse derived fuel applications
WO2020086927A1 (en) * 2018-10-26 2020-04-30 Saint Louis University Peptides for inducing heterosubtypic influenza t cell responses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) * 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
EP0692973A1 (en) * 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide coated dendritic cells as immunogens
WO1995009642A1 (en) * 1993-10-05 1995-04-13 Ludwig Institute For Cancer Research Method for provoking immunity by peptides labelled with a photoactivatable group which binds to mhc molecules
WO1996022067A2 (en) * 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics

Also Published As

Publication number Publication date
EP0900380B1 (en) 2003-07-09
AU738649B2 (en) 2001-09-20
DK0900380T3 (da) 2003-11-03
WO1997041440A1 (en) 1997-11-06
CA2252675A1 (en) 1997-11-06
DE69723434T2 (de) 2004-05-19
DE69723434D1 (de) 2003-08-14
JP4108126B2 (ja) 2008-06-25
JP2000510689A (ja) 2000-08-22
ATE244891T1 (de) 2003-07-15
AU2410697A (en) 1997-11-19
US20070025968A1 (en) 2007-02-01
ES2205209T3 (es) 2004-05-01
EP0900380A1 (en) 1999-03-10

Similar Documents

Publication Publication Date Title
PT900380E (pt) Metodos para seleccionar e produzir epitopos peptidicos de celulas t e vacinas que incorporam os referidos epitopos seleccionados
Ghosh et al. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
HUP0402048A2 (hu) Eljárás specifikus patogének antigénjeinek azonosítására, izolálására és előállítására
CY1113044T1 (el) Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων
ATE429448T1 (de) Peptidzusammensetzung als immunogen zur allergiebehandlung.
AR020102A1 (es) Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
Hanna et al. Synthetic protein conjugate vaccines provide protection against Mycobacterium tuberculosis in mice
CA2272338A1 (en) Immunization of infants
AU1800597A (en) Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
Rolph et al. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes
Robinson et al. High levels of protection induced by a 40-mer synthetic peptide vaccine against the intestinal nematode parasite Trichinella spiralis.
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
WO2000000156A3 (en) Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands
Gu et al. A multiple antigen peptide vaccine containing CD4+ T cell epitopes enhances humoral immunity against Trichinella spiralis infection in mice
GB2355983A (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
Wolpert et al. Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells
Ricciardi et al. Immune mechanisms involved in schistosoma mansoni-Cathepsin B vaccine induced protection in mice
Maletto et al. CpG oligodeoxinucleotides functions as an effective adjuvant in aged BALB/c mice
Waters et al. Cellular immune responses of pigs induced by vaccination with either a whole cell sonicate or pepsin-digested Brachyspira (Serpulina) hyodysenteriae bacterin
Myers et al. Monophosphoryl lipid A behaves as a T-cell-independent type 1 carrier for hapten-specific antibody responses in mice
Lv et al. Expression profile, localization of an 8-kDa calcium-binding protein from Schistosoma japonicum (SjCa8), and vaccine potential of recombinant SjCa8 (rSjCa8) against infections in mice
Paul et al. Immunological evaluation of fusion protein of Brugia malayi abundant larval protein transcript-2 (BmALT-2) and Tuftsin in experimental mice model
Souza et al. Extracts of Ascaris suum egg and adult worm share similar immunosuppressive properties